PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Misses Expectations By $0.76 EPS

PTC Therapeutics (NASDAQ:PTCT) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.76), FiscalAI reports. The firm had revenue of $357.81 million for the quarter, compared to analyst estimates of $306.43 million. The company’s revenue was up 69.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 EPS.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Guidance was raised after a record quarter: Third-quarter total revenue reached $358 million, including $276 million in product revenue, and 2026 product revenue guidance increased to $960 million–$990 million. Management also reiterated its expectation to reach cash-flow breakeven this year.
• SEPHIENCE launch momentum remains strong: Global SEPHIENCE revenue was $182 million, up more than 20% sequentially, with over 2,000 active patients worldwide and strong adherence. PTC said the U.S. launch is entering a durable growth phase and maintained its confidence in a $2 billion-plus peak-sales opportunity.
• ST-920 adds a potentially near-term growth driver: PTC expects to complete its rolling BLA submission for the Fabry gene therapy in the fourth quarter, with potential approval and launch in 2027. The company said the $111 million acquisition could be accretive in 2027 and noted ST-920’s RMAT designation may support priority review.
• Mature DMD products face increasing pressure: A new Emflaza generic entrant has significantly reduced pricing, while Translarna’s third-quarter revenue benefited from an unexpected Russian government order that PTC does not expect to repeat in the fourth quarter.
• Votoplam’s regulatory discussion was delayed: The FDA Type C meeting on the Huntington’s disease program is now expected in the first quarter of 2027 rather than late 2026, although global enrollment in the 770-patient INVEST-HD Phase III study continues.

PTC Therapeutics Trading Up 2.3%

PTCT stock traded up $1.44 during midday trading on Thursday, hitting $64.46. The stock had a trading volume of 1,524,172 shares, compared to its average volume of 996,871. The firm has a market capitalization of $5.38 billion, a price-to-earnings ratio of -111.14, a P/E/G ratio of 1.90 and a beta of 0.49. PTC Therapeutics has a 52 week low of $58.80 and a 52 week high of $90.87. The stock has a 50-day simple moving average of $65.57 and a 200 day simple moving average of $70.87.

Insiders Place Their Bets

In other news, VP Mark Boulding sold 435 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the completion of the transaction, the vice president directly owned 105,272 shares of the company’s stock, valued at approximately $6,754,251.52. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the company’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $59.61, for a total transaction of $149,025.00. Following the completion of the sale, the director directly owned 1,291,594 shares in the company, valued at approximately $76,991,918.34. The trade was a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,370 shares of company stock worth $5,322,261 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Analysts Set New Price Targets

PTCT has been the subject of a number of research reports. Morgan Stanley increased their price target on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Zacks Research downgraded shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Barclays upped their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. UBS Group assumed coverage on shares of PTC Therapeutics in a research note on Thursday, October 15th. They issued a “buy” rating and a $90.00 target price for the company. Finally, Raymond James Financial set a $106.00 target price on PTC Therapeutics in a research report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.93.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.